Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

European Funding Boosts Research into Breast Cancer

29.04.2005


As cancer is the main cause of death among women aged 35 to 64 the EU’s Sixth Framework Programme (FP6) has agreed to provide seven million euros for a new Network of Excellence called TRANS-BIG, aimed at addressing the treatment of breast cancer.



TRANS-BIG aims to refine the diagnosis of breast cancer in a way that will enable specialists reduce the number of women being over treated by better identification of those who will benefit from treatment.

“Under the present system many patients are over treated while only a few derive a considerable benefit”, says Dr Robert Leonard from the South West Wales Cancer Institute. “By refining the prognosis for a better definition of who needs treatment we hope to significantly reduce the proportion of women receiving unnecessary chemotherapy and reduce their exposure to toxicity and harmful long-term side effects. At the same time, this will considerably reduce the cost of breast cancer therapy and its burden on European health care systems.


“Indeed, two decades of clinical trials have shown that although chemotherapy increases the survival rate from 2 to 12 per cent, it can also be the cause of secondary cancers, cardiac toxicity, early menopause and a reduction in cognitive functions.”

The TRANS-BIG Network of Excellence, based on the principles of translational research - ’bench to bedside’ and ’bedside to bench’ - will tackle the fragmentation which currently exists in this field of research and accelerate the clinical applications of biological discoveries.

With 39 partners from 21 countries the TRANS-BIG consortium has the critical mass expertise needed to create a fully coherent research force of leading specialists in Europe. This in itself will help overcome the existing fragmentation of effort and give Europe the competitive approach it needs to take the lead in breast cancer therapy internationally.

The first target of TRANS-BIG is the development of its first trial - MINDACT (Microarray for Node Negative Disease may avoid Chemotherapy) - using microarrays to identify the specific molecular make up (’signature’) of a tumour. Although still in its infancy, this technology is expected to allow for a better selection of the patients that actually do need chemotherapy.

“We believe that the results of MINDACT will show that using the new technology to assess risk will result in fewer women being treated unnecessarily”, added Dr Leonard. “This, in turn, will mean that fewer women will suffer from the unpleasant side effects of chemotherapy. Not only will the overall quality of life of breast cancer patients be improved, but the health care costs associated with such cancer treatment will be reduced as well, thus providing a significant benefit to society. Additionally, by more accurately choosing patients who do need chemotherapy the final outcome in terms of survival is expected to be better.

By conducting translational research in an integrated way, the project will ensure that the best facilities from the leading cancer research and treatment institutes will be shared, thus decreasing cost and increasing effectiveness.

“Improving the way we diagnose and treat breast cancer is crucial if we are to prevent many women receiving unnecessary, and costly, chemotherapy treatment in the future”, says Claire Horton, FP6UK’s National Contact Point for ’Life sciences, genomics and biotechnology for health. “The fight against cancer is a priority issue for the EU as it is estimated that our increasingly ageing population will lead to an extra 250,000 cancer diagnoses every year in Europe by 2020.

“The current Framework Programme (FP6) runs until 2006 and organisations wanting free information on how to access some of the 19 billion euros available should log on to http://fp6uk.ost.gov.uk or call central telephone support on 0870 600 6080.”

Dave Sanders | alfa
Further information:
http://fp6uk.ost.gov.uk

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Polymers Based on Boron?

18.01.2018 | Life Sciences

Bioengineered soft microfibers improve T-cell production

18.01.2018 | Life Sciences

World’s oldest known oxygen oasis discovered

18.01.2018 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>